A new genetic test called MammaPrint is helping many breast cancer patients. This test determines the risk of cancer ...

Basel: Roche has announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has ...

The Itovebi, Ibrance, and fulvestrant combination demonstrated improved survival outcomes versus placebo in a Phase III trial.

In combination with Pfizer’s CDK4/6 inhibitor Ibrance (palbociclib) and anti-oestrogen drug Faslodex (fulvestrant), Itovebi ...

Roche (OTCQX:RHHBY) (OTCQX:RHHBF) said that an advisory panel of the European Medicines Agency (EMA), endorsed its Itovebi ...

CHICAGO -- Adding the PI3K-pathway inhibitor inavolisib (Itovebi) to palbociclib (Ibrance) and fulvestrant significantly ...

The latest readout from INAVO120 marks the first time a PI3K-inhibiting targeted treatment has shown an overall survival advantage.

ILC accounts for 10–15% of breast cancers and often goes undetected. Learn about its characteristics, treatments, and future ...

Sometimes breast cancer can emerge between routine mammograms. Five years after recovery, one patient's story reinforces the ...

Sarrah Strimel Bentley and her boyfriend, James, were walking their dog at sunset when she felt an itch under her armpit. She ...

Panelists discuss how molecular testing and liquid biopsies are crucial for tracking estrogen receptor 1 (ESR1) mutations in ...

For Black women with HR–positive/ERBB2–negative breast cancer, a higher percentage of West African ancestry is associated ...